In this episode, David Flores sits down with Donald Currie, the Clinical Director for Dimensions Retreats in Algonquin Highlands. He joins us alongside world-renowned cultural anthropologist, ethnobotanist, author, and photographer Wade Davis to discuss the launch of Dimensions’ new Zen Plus program which has its sight on taking the world of psychedelic retreat centers to a whole new level.
Hey guys! This is an impromptu video because I have some pretty cool MindMed News! MindMed is being added to the FTSE! Will mmed stock rocket up on Monday? How will MindMed’s addition to the FTSE will affect the stock and what even is the FTSE? These are all the topics we shall cover in this video.
I know we’re all impatiently waiting for MindMed to be uplisted on to the NASDAQ. But this MMED being added to the FTSE is also good news because it contributes to the company’s legitimacy! This is very goo new for MindMed and the mindmed stock price, at least in my opinion!
I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
In this episode of the Psychedelic Spotlight podcast, we feature…
In today’s episode, we discuss the results of the much awaited phase 2b clinical trial using psilocybin (comp360) to treat treatment-resistant-depression. This Compass Pathways (Nasdaq: CMPS) trial is so important for a couple of reasons: first, it is the largest ever psychedelics clinical trial, with 219 people completing the trial; and second because it is the furthest progressed psilocybin trial ever, being in phase 2b.
So what did the results say? Can Magic Mushrooms treat depression? Can Psychedelics help Mental Health?
Well, the results are mixed. About a quarter of the people who underwent Compass Pathways psychedelic therapy program, who received 25 mg of psilocybin (Comp 360), entered remission after 12 weeks. And almost a third of individuals in this group saw their depression symptoms decrease by 50% or more, as measured by the MADRS scale. This is more than double the success rate for the control group, showing strong significant effects of psilocybin therapy on depression. Therefore, it is clear that psychedelics like psilocybin CAN help mental health… at least somewhat
However, many, myself included, were hoping for stronger results, such as the MDMA to treat PTSD phase 3 results that MAPS released earlier this year. This led to disappointment at the positive results, as they were not as game changing as we had hoped.
In this episode, we describe Compass Pathways’ psilocybin for depression clinical trial, explain the results, and then try to put said results into context. We finish by looking towards the future, and discussing where Compass Pathways, and other psychedelic medicines companies like MindMed, Cybin and Small Pharma, should go from here.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Links:
Compass Results: https://ir.compasspathways.com/static-files/0f9fbce8-2619-438b-a6ba-5bbe2ba08cf6
Montgomery-Asberg Depression Rating Scale (MADRS):
https://en.wikipedia.org/wiki/Montgomerysberg_Depression_Rating_Scale
MAPS MDMA-PTSD Study:
https://www.nytimes.com/2021/05/03/health/mdma-approval.html
Comp 360 Open Label Study:
https://www.globenewswire.com/en/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html
MindMed Psilocybin SSRI Study:
https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #psilocybin #depression
In our previous video, we discussed the upcoming IPO of Horizons Psychedelic ETF (PSYK).
Recently, on January 27th, PSYK began trading on the Canadian NEO Stock Exchange.
In this episode we are going to discuss the psychedelic ETF and what it means for MindMed, NUMI, Compass Pathways and other stocks in the psychedelic sector.
We will cover a few things such as:
– PSYK’s fundamentals
– PSYK’s CEO Steve Hawkins
-Is Horizons ETF actively or passively managed?
– What psychedelic stocks are included in the ETF?
– How often does th ETF reorganize its stock holdings?
– How is the size of the individual stocks’ position decided on?
– Is it worth investing in PSYK now?
– What will happen to MindMed (MMED/MMEDF), Numinus Wellness (NUMI), Compass Pathways (CMPS) and the other stocks once they are included?
***A quick reminder, the psychedelic sector is at a VERY early stage, and all of these companies, large-cap and small cap alike, will need to attract more funding to complete their clinical trials and bring their products to market. PSYK will however contribute to this sector as it will bring more funding to the industry as a whole, which will both help individual companies and the wider mission of treating mental health disorders.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#PSYK #MindMed #MMED
“Psychedelics and plant-based medicines are powerful tools in the process of healing, particularly for the most marginalized folks living under empire, who are underserved, underrepresented and experience the highest rates of violence. Marginalized communities already have limited access to healing spaces, so I think t’s important for folks invested in justice work to center and prioritize what nontraditional forms of healing look like for these communities.”
This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
